[A18-15] Fluticasone furoate/umeclidinium/vilanterol (COPD) – Benefit assessment according to §35a Social Code Book V
Last updated 16.08.2018
Project no.:
A18-15
Commission:
Commission awarded on 27.02.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Airways and respiratory system
Adults with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2 agonist
No statistically significant differences between the treatment groups in the relevant subpopulation of the study included; added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-46 | Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15 | Commission completed |
| A18-79 | Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-08-16 A G-BA decision was published.